Hospital & Healthcare Services · Founded 2000 · www.narayanahealth.org · BSE 539551 · NSE NH · ISIN INE410P01011
No Notes Added Yet
Business
Narayana Hrudayalaya Ltd. (NH) is one of India's leading multi-specialty healthcare providers, operating a chain of hospitals, heart centers, and primary care facilities. The company's core business model revolves around providing comprehensive medical services across various specialties, including cardiac sciences, oncology, nephrology, neurosciences, orthopaedics, and more. NH focuses on making high-quality healthcare accessible and affordable, often through a high-volume, asset-light (in some models) and scale-driven approach. It generates revenue primarily from patient services (consultations, surgeries, diagnostics, room rentals), pharmacy sales, and other related medical services.
Revenue Mix
While specific revenue breakdowns by specialty are not always publicly disaggregated, NH operates as a multi-specialty hospital chain. Its primary revenue streams come from:
In-patient services: Major surgeries, critical care, and long-term treatments.
Out-patient services: Consultations, diagnostic tests, and minor procedures.
Pharmacy sales: Dispensing medicines within hospital premises.
Other services: Medical tourism, health check-ups, and academic programs.
The company has a strong reputation and historical strength in cardiac sciences, which remains a significant contributor, alongside other growing specialties like oncology and nephrology. Its operations are spread across various Indian cities, with a notable presence in Karnataka and other eastern/western states, and also has an international hospital in the Cayman Islands.
Industry
The Indian healthcare sector is characterized by strong growth, driven by increasing disposable incomes, rising health awareness, a growing burden of lifestyle diseases, and under-penetration of healthcare services. The industry is fragmented, with a mix of large corporate hospital chains, standalone hospitals, and government-run facilities. Narayana Hrudayalaya is positioned as a prominent corporate hospital chain, known for its ability to perform high-volume, complex procedures at relatively affordable costs. Its 'health city' model in Bangalore and focus on economies of scale differentiate it within the competitive landscape, where it competes with other large chains like Apollo Hospitals, Fortis Healthcare, Max Healthcare, and smaller regional players. NH is particularly strong in tier-1 and tier-2 cities, aiming to cater to a broad economic spectrum.
MOAT
Scale and Volume: NH's ability to handle a high volume of complex procedures, particularly in cardiac care, allows for economies of scale, operational efficiency, and potentially lower costs per procedure, which can be passed on to patients.
Brand Reputation: A strong brand built on its founder's vision (Dr. Devi Shetty) and reputation for quality and affordability in complex surgeries, especially cardiac.
Talent Pool: Attracting and retaining a large pool of skilled doctors, surgeons, and medical professionals, especially for high-end specialties.
Cost-effectiveness: Known for offering high-quality care at relatively lower prices than some peers, particularly in complex interventions, appealing to a wider segment of the population and for medical tourism.
Growth Drivers
Increasing Healthcare Spending: Rising income levels, greater health insurance penetration, and a growing awareness of health are driving demand for quality healthcare services.
Demographic Shifts: An aging population and an increasing prevalence of chronic and lifestyle diseases necessitate more healthcare interventions.
Expansion & Capacity Addition: Organic expansion through new hospitals/beds and inorganic growth via acquisitions or partnerships in underserved or high-demand regions.
Medical Tourism: India's cost-effective quality healthcare attracts international patients, a segment NH can leverage.
Digital Health & Telemedicine: Adoption of digital platforms for consultations, diagnostics, and patient management can expand reach and efficiency.
Government Initiatives: Schemes like Ayushman Bharat (PM-JAY) can increase the patient base for empaneled hospitals like NH, particularly in secondary and tertiary care.
Risks
Regulatory Risks: Changes in healthcare policies, pricing controls for drugs and medical devices, and operational guidelines can impact profitability.
Doctor and Staff Retention: Intense competition for skilled medical professionals can lead to higher staff costs or challenges in talent acquisition.
High Capital Expenditure: Establishing and expanding hospitals requires significant capital investment, leading to potential debt and longer gestation periods for new projects.
Pricing Pressure: Competition and regulatory scrutiny can put downward pressure on treatment costs and profitability.
Medical Negligence & Litigation: Risks associated with medical errors, which can lead to reputational damage and legal liabilities.
Economic Downturns: Reduced disposable incomes or slower economic growth could impact elective procedures and patient footfall.
Management & Ownership
Narayana Hrudayalaya was founded by Dr. Devi Prasad Shetty, a renowned cardiac surgeon, who serves as the Chairman and Executive Director. The promoter group holds a significant stake in the company. Dr. Shetty's vision of making high-quality healthcare accessible and affordable forms the core philosophy of the organization. The management team includes experienced professionals from the healthcare and business sectors, steering the company's operational and strategic growth. The ownership structure reflects a typical promoter-led Indian company, with institutional investors and the public holding the remaining shares.
Outlook
Narayana Hrudayalaya is well-positioned to benefit from the secular growth trends in the Indian healthcare sector. Its established brand, focus on high-volume affordable care, and strong clinical outcomes provide a solid foundation. The company's strategy of expanding its presence and diversifying its specialty mix beyond cardiac sciences should drive future revenue and profitability.
However, the company faces inherent challenges related to capital-intensive growth, intense competition, regulatory uncertainties, and the ongoing need to attract and retain top medical talent. Managing operational efficiencies and maintaining profitability amidst pricing pressures will be crucial. The ability to successfully execute expansion plans while upholding its reputation for quality and affordability will determine its sustained success.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1204 | 1246 | 1306 | 1367 | 1335 | 1475 | 1507 | 1644 | 2151 | 2594 |
| Other Income | 18 | 24 | 23 | 24 | 18 | 27 | 24 | 24 | 23 | 29 |
| Total Income | 1222 | 1270 | 1330 | 1390 | 1353 | 1502 | 1531 | 1668 | 2174 | 2623 |
| Total Expenditure | 925 | 955 | 1004 | 1058 | 1027 | 1118 | 1170 | 1241 | 1784 | 2084 |
| Operating Profit | 297 | 315 | 326 | 332 | 326 | 385 | 361 | 426 | 390 | 539 |
| Interest | 25 | 28 | 34 | 35 | 37 | 41 | 45 | 42 | 65 | 91 |
| Depreciation | 63 | 65 | 61 | 65 | 70 | 83 | 84 | 87 | 122 | 154 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | -8 | 0 | 0 | -51 | -0 |
| Profit Before Tax | 209 | 222 | 231 | 232 | 220 | 253 | 231 | 297 | 152 | 294 |
| Provision for Tax | 20 | 34 | 30 | 33 | 26 | 57 | 35 | 37 | 22 | 64 |
| Profit After Tax | 188 | 188 | 201 | 199 | 194 | 196 | 196 | 260 | 130 | 230 |
| Adjustments | -0 | 3 | 1 | -1 | -1 | 1 | 0 | -1 | -3 | -6 |
| Profit After Adjustments | 188 | 191 | 201 | 199 | 193 | 197 | 197 | 258 | 127 | 224 |
| Adjusted Earnings Per Share | 9.2 | 9.3 | 9.9 | 9.7 | 9.4 | 9.7 | 9.6 | 12.6 | 6.2 | 11 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1364 | 1614 | 1878 | 2281 | 2861 | 3128 | 2583 | 3701 | 4525 | 4890 | 5483 | 7896 |
| Other Income | 8 | 16 | 23 | 19 | 19 | 28 | 27 | 35 | 65 | 92 | 92 | 100 |
| Total Income | 1372 | 1630 | 1902 | 2300 | 2880 | 3156 | 2611 | 3736 | 4590 | 4982 | 5575 | 7996 |
| Total Expenditure | 1238 | 1437 | 1649 | 2061 | 2566 | 2701 | 2394 | 3038 | 3544 | 3745 | 4190 | 6279 |
| Operating Profit | 133 | 193 | 252 | 239 | 314 | 455 | 217 | 698 | 1046 | 1237 | 1385 | 1716 |
| Interest | 45 | 33 | 28 | 55 | 81 | 94 | 82 | 76 | 84 | 112 | 163 | 243 |
| Depreciation | 68 | 76 | 80 | 100 | 137 | 186 | 184 | 183 | 210 | 241 | 278 | 447 |
| Exceptional Income / Expenses | 0 | -11 | -1 | 1 | 0 | -11 | 0 | 0 | 0 | 0 | -8 | -51 |
| Profit Before Tax | 21 | 51 | 135 | 80 | 93 | 161 | -56 | 430 | 752 | 884 | 936 | 974 |
| Provision for Tax | 15 | 30 | 52 | 29 | 34 | 42 | -42 | 88 | 145 | 98 | 146 | 158 |
| Profit After Tax | 6 | 21 | 83 | 51 | 59 | 119 | -14 | 342 | 607 | 786 | 790 | 816 |
| Adjustments | -23 | 0 | 0 | -0 | -0 | -0 | -0 | 0 | 0 | 3 | 0 | -10 |
| Profit After Adjustments | -17 | 21 | 83 | 51 | 59 | 119 | -14 | 342 | 607 | 789 | 790 | 806 |
| Adjusted Earnings Per Share | -0.8 | 1 | 4.1 | 2.5 | 2.9 | 5.8 | -0.7 | 16.7 | 29.7 | 38.6 | 38.7 | 39.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 12% | 14% | 12% | 15% |
| Operating Profit CAGR | 12% | 26% | 25% | 26% |
| PAT CAGR | 1% | 32% | 46% | 63% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 13% | 29% | 33% | 20% |
| ROE Average | 24% | 30% | 23% | 13% |
| ROCE Average | 22% | 28% | 22% | 16% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 768 | 876 | 963 | 1036 | 1081 | 1136 | 1120 | 1489 | 2131 | 2884 | 3626 |
| Minority's Interest | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| Borrowings | 207 | 188 | 180 | 696 | 725 | 619 | 504 | 432 | 626 | 1195 | 1966 |
| Other Non-Current Liabilities | 51 | 178 | 181 | 285 | 316 | 532 | 440 | 427 | 410 | 429 | 469 |
| Total Current Liabilities | 343 | 315 | 323 | 510 | 510 | 602 | 703 | 784 | 988 | 1224 | 1248 |
| Total Liabilities | 1370 | 1556 | 1647 | 2528 | 2633 | 2889 | 2768 | 3133 | 4157 | 5732 | 7359 |
| Fixed Assets | 913 | 1055 | 1082 | 1848 | 1838 | 2092 | 1961 | 1980 | 2336 | 2651 | 4266 |
| Other Non-Current Assets | 197 | 216 | 263 | 200 | 267 | 211 | 142 | 240 | 526 | 1022 | 442 |
| Total Current Assets | 260 | 272 | 302 | 479 | 527 | 586 | 665 | 913 | 1295 | 2059 | 2604 |
| Total Assets | 1370 | 1556 | 1647 | 2528 | 2633 | 2889 | 2768 | 3133 | 4157 | 5732 | 7359 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 27 | -53 | -11 | 31 | -5 | 84 | 92 | 90 | 149 | 145 | 242 |
| Cash Flow from Operating Activities | 77 | 174 | 219 | 182 | 279 | 443 | 304 | 485 | 1085 | 1067 | 986 |
| Cash Flow from Investing Activities | -222 | -150 | -146 | -534 | -161 | -189 | -113 | -267 | -1174 | -1458 | -1325 |
| Cash Flow from Financing Activities | 140 | 18 | -45 | 315 | -27 | -247 | -194 | -159 | 88 | 488 | 544 |
| Net Cash Inflow / Outflow | -5 | 42 | 28 | -36 | 90 | 8 | -2 | 59 | -2 | 97 | 205 |
| Closing Cash & Cash Equivalent | 21 | -11 | 17 | -5 | 84 | 92 | 90 | 149 | 145 | 242 | 447 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.84 | 1.04 | 4.06 | 2.51 | 2.9 | 5.82 | -0.7 | 16.74 | 29.68 | 38.62 | 38.66 |
| CEPS(Rs) | 3.71 | 4.74 | 7.97 | 7.41 | 9.62 | 14.92 | 8.28 | 25.72 | 39.96 | 50.28 | 52.26 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2.5 | 4 | 4.5 |
| Book NAV/Share(Rs) | 38.42 | 42.7 | 46.67 | 50.02 | 52.78 | 55.42 | 54.64 | 72.69 | 104.26 | 141.1 | 177.44 |
| Core EBITDA Margin(%) | 9.21 | 10.98 | 12.18 | 9.65 | 10.31 | 13.65 | 7.32 | 17.92 | 21.67 | 23.42 | 23.59 |
| EBIT Margin(%) | 4.77 | 5.23 | 8.67 | 5.92 | 6.09 | 8.16 | 1.02 | 13.67 | 18.47 | 20.36 | 20.04 |
| Pre Tax Margin(%) | 1.51 | 3.16 | 7.21 | 3.52 | 3.26 | 5.16 | -2.17 | 11.61 | 16.61 | 18.08 | 17.06 |
| PAT Margin (%) | 0.43 | 1.29 | 4.42 | 2.25 | 2.07 | 3.81 | -0.55 | 9.24 | 13.41 | 16.07 | 14.4 |
| Cash Profit Margin (%) | 5.45 | 6.01 | 8.67 | 6.64 | 6.87 | 9.75 | 6.55 | 14.2 | 18.05 | 21.01 | 19.48 |
| ROA(%) | 0.47 | 1.42 | 5.18 | 2.46 | 2.3 | 4.31 | -0.51 | 11.59 | 16.64 | 15.9 | 12.07 |
| ROE(%) | 0.88 | 2.54 | 9.09 | 5.2 | 5.64 | 10.77 | -1.27 | 26.3 | 33.55 | 31.35 | 24.27 |
| ROCE(%) | 6.36 | 7.45 | 14.09 | 8.94 | 9.34 | 13.61 | 1.46 | 26.83 | 33.92 | 27.58 | 21.62 |
| Receivable days | 37.08 | 33.33 | 30 | 34.88 | 34.79 | 30.85 | 38.21 | 35.27 | 35.02 | 31.85 | 32.53 |
| Inventory Days | 13.45 | 11.42 | 9.92 | 10.88 | 10.64 | 8.37 | 7.64 | 5.29 | 5.28 | 6.77 | 7.33 |
| Payable days | 154.68 | 139.96 | 153.91 | 167.76 | 169.49 | 170.21 | 207.83 | 172.49 | 193.96 | 215.88 | 189.19 |
| PER(x) | 0 | 274.98 | 77.14 | 110.9 | 73.83 | 42.53 | 0 | 44.59 | 26.08 | 33.15 | 43.74 |
| Price/Book(x) | 0 | 6.69 | 6.72 | 5.57 | 4.05 | 4.46 | 7.43 | 10.27 | 7.42 | 9.07 | 9.53 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0.47 | 0.4 | 0 | 0.13 | 0.32 | 0.31 | 0.27 |
| EV/Net Sales(x) | 0.39 | 3.76 | 3.51 | 2.83 | 1.78 | 1.81 | 3.4 | 4.22 | 3.58 | 5.56 | 6.59 |
| EV/Core EBITDA(x) | 3.99 | 31.42 | 26.14 | 27.04 | 16.19 | 12.43 | 40.55 | 22.4 | 15.49 | 21.98 | 26.08 |
| Net Sales Growth(%) | 24.54 | 18.33 | 16.38 | 21.44 | 25.43 | 9.33 | -17.42 | 43.29 | 22.25 | 8.08 | 12.12 |
| EBIT Growth(%) | -25.76 | 29.68 | 93.15 | -17.18 | 24.81 | 46.47 | -89.84 | 1427.48 | 65.19 | 19.15 | 10.37 |
| PAT Growth(%) | -83.22 | 251.2 | 298.55 | -38.05 | 5.78 | 100.84 | -111.67 | 4687.9 | 77.3 | 29.58 | 0.49 |
| EPS Growth(%) | -149.7 | 223.96 | 291.15 | -38.17 | 15.23 | 100.98 | -112.03 | 2491.91 | 77.3 | 30.12 | 0.11 |
| Debt/Equity(x) | 0.47 | 0.3 | 0.23 | 0.78 | 0.75 | 0.63 | 0.55 | 0.37 | 0.36 | 0.5 | 0.61 |
| Current Ratio(x) | 0.76 | 0.86 | 0.93 | 0.94 | 1.03 | 0.97 | 0.95 | 1.16 | 1.31 | 1.68 | 2.09 |
| Quick Ratio(x) | 0.61 | 0.71 | 0.77 | 0.78 | 0.87 | 0.87 | 0.88 | 1.09 | 1.24 | 1.59 | 2 |
| Interest Cover(x) | 1.46 | 2.53 | 5.91 | 2.47 | 2.16 | 2.72 | 0.32 | 6.65 | 9.94 | 8.92 | 6.73 |
| Total Debt/Mcap(x) | 0 | 0.04 | 0.03 | 0.14 | 0.19 | 0.14 | 0.07 | 0.04 | 0.05 | 0.06 | 0.06 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.27 | 63.27 |
| FII | 11.51 | 10.91 | 10.01 | 9.68 | 9.44 | 9.66 | 10.46 | 10.49 | 11.1 | 9.98 |
| DII | 10.23 | 9.51 | 8.23 | 7.9 | 8.69 | 8.52 | 8.09 | 7.76 | 7.91 | 9.15 |
| Public | 14.41 | 15.73 | 17.91 | 18.57 | 18.02 | 17.97 | 17.6 | 17.9 | 17.71 | 17.6 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 13.05 | 13.05 | 13.05 | 13.05 | 13.05 | 13.05 | 13.05 | 13.05 | 12.93 | 12.93 |
| FII | 2.35 | 2.23 | 2.05 | 1.98 | 1.93 | 1.97 | 2.14 | 2.14 | 2.27 | 2.04 |
| DII | 2.09 | 1.94 | 1.68 | 1.61 | 1.78 | 1.74 | 1.65 | 1.59 | 1.62 | 1.87 |
| Public | 2.94 | 3.21 | 3.66 | 3.79 | 3.68 | 3.67 | 3.6 | 3.66 | 3.62 | 3.6 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +12% | +14% | +12% | +15% |
| Operating Profit CAGR | +12% | +26% | +25% | +26% |
| PAT CAGR | +1% | +32% | +46% | +63% |
| Share Price CAGR | +13% | +29% | +33% | +20% |
| ROE Average | +24% | +30% | +23% | +13% |
| ROCE Average | +22% | +28% | +22% | +16% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.27 | 63.27 |
| FII | 11.51 | 10.91 | 10.01 | 9.68 | 9.44 | 9.66 | 10.46 | 10.49 | 11.1 | 9.98 |
| DII | 10.23 | 9.51 | 8.23 | 7.9 | 8.69 | 8.52 | 8.09 | 7.76 | 7.91 | 9.15 |
| Public | 36.15 | 36.15 | 36.15 | 36.15 | 36.15 | 36.15 | 36.15 | 36.15 | 36.73 | 36.73 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 13.05 | 13.05 | 13.05 | 13.05 | 13.05 | 13.05 | 13.05 | 13.05 | 12.93 | 12.93 |
| FII | 2.35 | 2.23 | 2.05 | 1.98 | 1.93 | 1.97 | 2.14 | 2.14 | 2.27 | 2.04 |
| DII | 2.09 | 1.94 | 1.68 | 1.61 | 1.78 | 1.74 | 1.65 | 1.59 | 1.62 | 1.87 |
| Public | 7.39 | 7.39 | 7.39 | 7.39 | 7.39 | 7.39 | 7.39 | 7.39 | 7.51 | 7.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 | 20.44 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.